Cortigent (CRGT) Market Cap to Earnings
Cortigent, Inc. (CRGT) relies on a system of proven parts suppliers, which ensures the stability of system assembly. The price action, where the indicator stands at , helps track business dynamics. Growth is protected by patents for the Orion platforms and strict FDA control. However, geopolitical fragmentation and microchip shortages are hindering global testing and the certification of vision-restoration devices.
Comprehensive metric breakdowns and analytics for Cortigent Inc (CRGT)
- stock value and consensus price forecast:
- market capitalization details:
- book value of equity indicators:
- company liabilities and liquidity data:
Total Debt to Capital Coefficient Cortigent, Inc.|CRGT - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Cortigent Medical|CRGT - Company Aggregate Debts|Debts to Book Value Cortigent, Inc.|CRGT - Company Long-Term Debt|Company Short-Term Indebtedness Cortigent|Intermediate Liquidity Ratio cortigent.com
- earnings and valuation multiples indicators:
CRGT - Net Income|Expected Net Income Cortigent, Inc.|CRGT - P/E Multiple|Market Cap to Projected Earnings Cortigent Medical|CRGT - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Cortigent, Inc.|CRGT - Operating profit EBITDA|Net earnings per share for the last 12 months Cortigent|CRGT - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months cortigent.com|CRGT - Earnings growth in current year|Expected earnings per share growth for next year Cortigent, Inc.
Summary company analysis:CRGT (cortigent.com)
To isolate the fundamental stability of Cortigent, Inc. (CRGT) from market noise, it is necessary to evaluate the efficiency of profit generation. The P/E ratio measures the investment payback period through the ratio of market capitalization to net income. By analyzing the company's price-to-earnings trend, an investor can identify asset overvaluation. For biotech, this metric depends critically on the success of neural interface clinical trials. Government funding for innovation directly impacts future profitability.
Analysis of competing companies
Price to Earnings Ratio biogen.com (BIIB)|Price to Earnings Ratio Neurocrine Biosciences, Inc. (NBIX)|RGC - Market Cap to Earnings|Price to Earnings Ratio Axsome Therapeutics Inc AXSM|Company Value to Net Income ACAD|XENE: Price to Earnings Ratio|vikingtherapeutics.com - Market Price to Net Income Ratio|SUPN: P/E Multiple|CPRX - Business Payback Period|DNLI (Denali Therapeutics Inc) - P/E Multiple|HRMY - Market Cap to Net Income Ratio|P/E Multiple BHVN|AMLX - Market Cap to Earnings|Price to Earnings Ratio Trevi Therapeutics, Inc. TRVI|PRAX: Price to Earnings Multiple|AVXL: Price to Earnings Ratio|CeriBell EEG - Market Price to Net Income Ratio|PRTA (prothena.com) - Price to Earnings Ratio|Alector - Company Value to Net Income|ANNX (Annexon) - P/E Multiple|Omeros Corp. (OMER) - Business Payback Period|Price to Earnings Ratio Neurogene Corp (NGNE)|AC Immune Inc - Price to Earnings Multiple|P/E Multiple VYGR (Voyager Therapeutics)|NMRA - Price to Earnings Ratio|SCLX: Price to Earnings Ratio|Business Payback Period Tevogen Bio Holdings Inc. TVGN|ACOG: P/E Multiple|Price to Earnings Ratio Cognition Therapeutics Inc.|Price to Earnings Ratio Inhibikase Therapeutics|SAVA: Company Value to Net Income|P/E Multiple ASRT|coyatherapeutics.com (COYA) - Market Cap to Net Income Ratio|Vistagen - Price to Earnings Ratio|Market Price to Net Income Ratio OVID (Ovid Therapeutics Inc)|ABOS - Price to Earnings Ratio|CRVO (cervomed.com) - Price to Earnings Multiple|ATHE: P/E Multiple|Market Cap to Earnings Clene (CLNN)|Price to Earnings Ratio PEPG|P/E Multiple Jupiter Neurosciences, Inc.|Price to Earnings Ratio Relmada Therapeutics (RLMD)|ANVS (annovisbio.com) - Company Value to Net Income|Price to Earnings Ratio Grace Therapeutics GRCE|Firefly Neuroscience, Inc. (AIFF) - Market Cap to Earnings|ANEW Medical, Inc. - P/E Multiple|NeuroSense Therapeutics (NRSN) - Price to Earnings Ratio|Reviva Pharmaceuticals (RVPH) - Price to Earnings Ratio|Market Cap to Earnings MetaVia (MTVA)|Price to Earnings Ratio NeurAxis|HSDT: Company Value to Net Income|Price to Earnings Ratio PASG (Passage Bio, Inc.)|Market Price to Net Income Ratio NEUP|P/E Multiple NERV (Minerva Neurosciences)|Business Payback Period athira.com (ATHA)|Addex Therapeutics Ltd - P/E Multiple|Market Cap to Net Income Ratio Alzamend Neuro, Inc. (ALZN)|CYCN: P/E Multiple|Market Cap to Earnings Protagenic Therapeutics, Inc. (PTIX)|Price to Earnings Ratio Pasithea Therapeutics Corp|Price to Earnings Multiple ATXI (avenuetx.com)|Price to Earnings Ratio BCLI (BrainStorm Cell Therapeutics)|Market Price to Net Income Ratio CARA|Chromocell Therapeutics Corporation - Price to Earnings Ratio|Company Value to Net Income ELYM|Intra-Cellular - P/E Multiple|Business Payback Period longboardpharma.com LBPH|Marinus Pharmaceuticals, Inc. (MRNS) - Price to Earnings Ratio|Price to Earnings Multiple NKGN|NRBO (NeuroBo) - P/E Multiple|Price to Earnings Ratio Sage Therapeutics Inc (SAGE)|Price to Earnings Ratio SNPX (Synaptogenix, Inc.)|Business Payback Period trevena.com|P/E Multiple VIGL (Vigil Neuroscience, Inc.)|WENA - Price to Earnings Ratio|CERE - Price to Earnings Ratio
